

GLAXOSMITHKLINE PLC

Form 6-K

July 18, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 18 July 2016

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

--

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr D S Redfern
 b) Position/status Chief Strategy Officer

c) Initial notification/ amendment Initial notification

Details of the issuer, emission allowance market

2. participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)

3. each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Description of the financial instrument
 a) Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882

instrument

b) Nature of the transaction
 Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 14 July 2016, on shares held through the Company's ShareReward Plan.

c) Price(s) and volume(s)
 Price(s) £16.6373
 Volume(s) 54

Aggregated information
 n/a (single transaction)

d) Aggregated volume
 Price

e) Date of the transaction
 2016-07-14

f) Place of the transaction
 London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)
Date: July 18, 2016

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc